10x Genomics Debt to Equity Ratio 2018-2025 | TXG
Current and historical debt to equity ratio values for 10x Genomics (TXG) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. 10x Genomics debt/equity for the three months ending June 30, 2025 was 0.00.
| 10x Genomics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-06-30 | $0.21B | $0.77B | 0.27 |
| 2025-03-31 | $0.20B | $0.71B | 0.28 |
| 2024-12-31 | $0.21B | $0.71B | 0.29 |
| 2024-09-30 | $0.22B | $0.72B | 0.30 |
| 2024-06-30 | $0.21B | $0.72B | 0.28 |
| 2024-03-31 | $0.20B | $0.72B | 0.28 |
| 2023-12-31 | $0.22B | $0.74B | 0.30 |
| 2023-09-30 | $0.20B | $0.75B | 0.27 |
| 2023-06-30 | $0.20B | $0.79B | 0.25 |
| 2023-03-31 | $0.21B | $0.80B | 0.26 |
| 2022-12-31 | $0.22B | $0.81B | 0.28 |
| 2022-09-30 | $0.22B | $0.78B | 0.28 |
| 2022-06-30 | $0.22B | $0.78B | 0.28 |
| 2022-03-31 | $0.20B | $0.81B | 0.24 |
| 2021-12-31 | $0.20B | $0.82B | 0.25 |
| 2021-09-30 | $0.19B | $0.80B | 0.24 |
| 2021-06-30 | $0.19B | $0.79B | 0.25 |
| 2021-03-31 | $0.20B | $0.75B | 0.27 |
| 2020-12-31 | $0.19B | $0.74B | 0.26 |
| 2020-09-30 | $0.22B | $0.83B | 0.26 |
| 2020-06-30 | $0.19B | $0.39B | 0.49 |
| 2020-03-31 | $0.20B | $0.41B | 0.49 |
| 2019-12-31 | $0.19B | $0.42B | 0.44 |
| 2019-09-30 | $0.00B | $0.00B | 0.00 |
| 2019-06-30 | $0.00B | $0.00B | 0.00 |
| 2019-03-31 | $0.00B | $0.00B | 0.00 |
| 2018-12-31 | $0.10B | $0.02B | 4.35 |
| 2017-12-31 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $1.898B | $0.611B |
| 10x Genomics Inc. is a life science technology company. It develops and sells instruments, consumables and software for analyzing biological systems. 10x Genomics Inc. is based in Pleasanton, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $48.330B | 58.97 |
| Tempus AI (TEM) | United States | $12.432B | 0.00 |
| Doximity (DOCS) | United States | $10.168B | 42.08 |
| Hims & Hers Health (HIMS) | United States | $9.340B | 75.98 |
| IRhythm Technologies (IRTC) | United States | $5.625B | 0.00 |
| Hinge Health (HNGE) | United States | $3.490B | 0.00 |
| Privia Health (PRVA) | United States | $2.882B | 180.23 |
| Heartflow (HTFL) | United States | $2.715B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.377B | 39.32 |
| Enovis (ENOV) | United States | $1.605B | 8.43 |
| Omnicell (OMCL) | United States | $1.601B | 32.73 |
| Clover Health Investments (CLOV) | United States | $1.368B | 0.00 |
| Azenta (AZTA) | United States | $1.346B | 58.74 |
| Phreesia (PHR) | United States | $1.319B | 0.00 |
| Schrodinger (SDGR) | United States | $1.309B | 0.00 |
| Claritev (CTEV) | United States | $1.141B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.807B | 0.00 |
| Evolent Health (EVH) | United States | $0.583B | 0.00 |
| Talkspace (TALK) | United States | $0.565B | 113.67 |
| Butterfly Network (BFLY) | United States | $0.563B | 0.00 |
| Veradigm (MDRX) | United States | $0.523B | 0.00 |
| Standard BioTools (LAB) | United States | $0.435B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.396B | 0.00 |
| Carlsmed (CARL) | United States | $0.363B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.295B | 0.00 |
| TruBridge (TBRG) | United States | $0.292B | 13.39 |
| CapsoVision (CV) | United States | $0.221B | 0.00 |
| Outset Medical (OM) | United States | $0.214B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.212B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.199B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.180B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.179B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.167B | 0.00 |
| CareCloud (CCLD) | United States | $0.147B | 8.06 |
| EUDA Health Holdings (EUDA) | Singapore | $0.127B | 0.00 |
| Pulmonx (LUNG) | United States | $0.078B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.075B | 0.00 |
| American Well (AMWL) | United States | $0.068B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.057B | 0.00 |
| HeartBeam (BEAT) | United States | $0.057B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.040B | 0.00 |
| 111 (YI) | China | $0.036B | 0.00 |
| Precipio (PRPO) | United States | $0.032B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.026B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.022B | 0.00 |
| Zhongchao (ZCMD) | China | $0.018B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.016B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.011B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.009B | 0.00 |
| PROFUSA (PFSA) | United States | $0.008B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.002B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.001B | 0.00 |